AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31195056 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic TMS
Number of subjects: 23
Study 31195056 — intervention group
Group type: COMPARATOR
Intervention: Sham tSMS
Number of subjects: 23
Study 28826968 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 30
Study 28826968 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 30
Study 26462677 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D movie
Number of subjects: 0
Study 26462677 — intervention group
Group type: COMPARATOR
Intervention: 2D movie
Number of subjects: 0
Study 23821397 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise30 (30 aircraft noise events per night, average SPL 60 dB(A))
Number of subjects: 75
Study 23821397 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise60 (60 aircraft noise events per night, average SPL 60 dB(A))
Number of subjects: 75
Study 23821397 — intervention group
Group type: COMPARATOR
Intervention: Control (no noise)
Number of subjects: 75
Study 21650084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel free base
Number of subjects: 0
Study 21650084 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel hydrochloride
Number of subjects: 0
Study 21650084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel free base with lansoprazole
Number of subjects: 0
Study 21650084 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel hydrochloride with lansoprazole
Number of subjects: 0
Study 18653184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/day, orally)
Number of subjects: 271
Study 18653184 — intervention group
Group type: COMPARATOR
Intervention: Intranasal buserelin acetate (900 microg/day, intranasally)
Number of subjects: 271
Study 17088316 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state free precession (SSFP) cardiovascular magnetic resonance
Number of subjects: 120
Study 15096442 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 27
Study 15096442 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (using laryngoscopy or intubating LMA)
Number of subjects: 27
Study 11497535 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens, 0.625 mg/d, plus trimonthly medroxyprogesterone acetate, 5 mg/d for 13 days (n = 45)
Number of subjects: 67
Study 11497535 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n = 22)
Number of subjects: 67
Study 11497535 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 67
Study 11497535 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 67
Study 9504447 — intervention group
Group type: EXPERIMENTAL
Intervention: Campbell's Center for Nutrition and Wellness plan (CCNW)
Number of subjects: 101
Study 9504447 — intervention group
Group type: COMPARATOR
Intervention: Dietary therapy with participant selected diet
Number of subjects: 101
Study 8040666 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/RT (chemotherapy with radiotherapy)
Number of subjects: 63
Study 8040666 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 63
Study 2568051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation
Number of subjects: 0
Study 2568051 — intervention group
Group type: COMPARATOR
Intervention: Placebo irradiation (control)
Number of subjects: 0
Study 31633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking at 0° (Group A)
Number of subjects: 52
Study 31633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking at 5° (Group B)
Number of subjects: 52
Study 31633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking at 10° (Group C)
Number of subjects: 52
Study 31633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking at 15° (Group D)
Number of subjects: 52
Study 31633440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no backward walking)
Number of subjects: 52
Study 28972419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred team-coaching approach
Number of subjects: 0
Study 28972419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28646887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg, administered once daily for 3 days.
Number of subjects: 0
Study 28646887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tPA 4 mg followed by normal saline), administered once daily for 3 days.
Number of subjects: 0
Study 26578852 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered tart cherries [CherryPURE(®)] (TC, n = 11)
Number of subjects: 23
Study 26578852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P, n = 12)
Number of subjects: 23
Study 24249853 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pharmacy practice experience (APPE) in medication therapy management (MTM)
Number of subjects: 464
Study 24249853 — intervention group
Group type: COMPARATOR
Intervention: Other fourth-year students
Number of subjects: 464
Study 21524808 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice with every-trial augmented feedback
Number of subjects: 0
Study 21524808 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice with every-trial augmented feedback
Number of subjects: 0
Study 21524808 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice with faded feedback
Number of subjects: 0
Study 21524808 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice with faded feedback
Number of subjects: 0
Study 19061704 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry with expiratory positive airway pressure (IS+EPAP)
Number of subjects: 34
Study 17333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg, once daily for 5 days)
Number of subjects: 120
Study 17333792 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (250 mg, 3 times a day for 5 days)
Number of subjects: 120
Study 12721685 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 671
Study 12721685 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses
Number of subjects: 671
Study 11566458 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg orally every 12 hours for 5 days)
Number of subjects: 166
Study 11566458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 9036746 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose heparin (100 U/kg bolus)
Number of subjects: 103
Study 9036746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (70 U/kg bolus)
Number of subjects: 103
Study 9036746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sheath removal (heparin stopped after procedure)
Number of subjects: 103
Study 9036746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-dose heparin and early sheath removal
Number of subjects: 103
Study 9036746 — intervention group
Group type: COMPARATOR
Intervention: Late sheath removal (heparin continued for 12 hours)
Number of subjects: 103
Study 8342759 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed CPB flow of 2.4 l.m-2
Number of subjects: 122
Study 8342759 — intervention group
Group type: COMPARATOR
Intervention: Tailored bypass flow to maintain venous return oxygen saturation of 75-80%
Number of subjects: 122
Study 3296129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thromboxane synthetase inhibitor (TSI)
Number of subjects: 15
Study 3296129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Inquiry-based learning approach with reflections on epistemic issues (intervention)
Number of subjects: 65
Study 31353458 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 65
Study 31353458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 30392388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (4-month concurrent training, 3 days/week, 60 min/session)
Number of subjects: 150
Study 30392388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 150
Study 30392388 — intervention group
Group type: COMPARATOR
Intervention: Counseling group
Number of subjects: 150
Study 26621631 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added post-fermentation
Number of subjects: 30
Study 26621631 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added (any form)
Number of subjects: 30
Study 26621631 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-12 (in any form)
Number of subjects: 30
Study 26621631 — intervention group
Group type: COMPARATOR
Intervention: Yogurt smoothie alone
Number of subjects: 30
Study 26621631 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-12 given in capsule form
Number of subjects: 30
Study 26621631 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with BB-12 added before fermentation
Number of subjects: 30
Study 24073964 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid-rich dietary pattern (CDP)
Number of subjects: 2983
Study 22075942 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg DIM daily for 6 months
Number of subjects: 551
Study 22075942 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 551
Study 20817384 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 361
Study 20817384 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 361
Study 17621671 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose sirolimus-eluting stents (SESs)
Number of subjects: 44
Study 15765241 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12
Study 15765241 — intervention group
Group type: COMPARATOR
Intervention: Sham training (placebo)
Number of subjects: 12
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 270
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 270
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 7.5 mg
Number of subjects: 270
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10.0 mg
Number of subjects: 270
Study 11982448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 7.5 mg
Number of subjects: 270
Study 11982448 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 270
Study 10596656 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Dental Anesthesia (EDA)
Number of subjects: 30
Study 10596656 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic ointment of Xylocaine 5%
Number of subjects: 30
Study 15714749 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of anticoagulants with antiplatelet agents with rheological effects (piracetam, buflomedil, pentoxifylline)
Number of subjects: 600
Study 15714749 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of anticoagulants with dipyridamole (antiplatelet agent without rheological effects)
Number of subjects: 600
Study 2065391 — intervention group
Group type: EXPERIMENTAL
Intervention: JWYY tablets
Number of subjects: 494
Study 2065391 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 494
Study 675836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diethylcarbamazine citrate (DEC) applied daily
Number of subjects: 0
Study 675836 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly topical applications of DEC emulsion
Number of subjects: 0
Study 675836 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of diethylcarbamazine citrate (DEC)
Number of subjects: 0
Study 31818845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal irinotecan added to standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Number of subjects: 0
Study 31818845 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy (5-fluorouracil/leucovorin with oxaliplatin and bevacizumab)
Number of subjects: 0
Study 28994364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (1-3 mg/kg/day every 8 hours)
Number of subjects: 42
Study 28994364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (1 mg/kg once a day)
Number of subjects: 42
Study 28994364 — intervention group
Group type: COMPARATOR
Intervention: Both sildenafil and tadalafil
Number of subjects: 42
Study 26125945 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered trimethoprim-sulfamethoxazole (TSM)
Number of subjects: 1073
Study 26125945 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered cefuroxime and metronidazole (CXM)
Number of subjects: 1073
Study 21357655 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 60
Study 21357655 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block appliance
Number of subjects: 60
Study 21357655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22093308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal detecting bulb (TDB) during endotracheal intubation
Number of subjects: 62
Study 22093308 — intervention group
Group type: COMPARATOR
Intervention: Control group (without TDB) during endotracheal intubation
Number of subjects: 62
Study 19860906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed letters of invitation
Number of subjects: 0
Study 19860906 — intervention group
Group type: COMPARATOR
Intervention: Advertisement in health plan's magazine
Number of subjects: 0
Study 16900802 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of prednisone daily for 5 consecutive days before the operation
Number of subjects: 36
Study 16900802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 36
Study 16787139 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0
Study 12900342 — intervention group
Group type: EXPERIMENTAL
Intervention: TAAA repair patients
Number of subjects: 19
Study 12900342 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 12900342 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL-deficient TAAA patient
Number of subjects: 19
Study 12900342 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL-sufficient TAAA patients
Number of subjects: 19
Study 10051860 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a walker
Number of subjects: 1212
Study 10051860 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of assistive devices (cane or walker)
Number of subjects: 1212
Study 7729788 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of oral DEX
Number of subjects: 6
Study 2040714 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 0
Study 2040714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7041450 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin E2 gel
Number of subjects: 143
Study 7041450 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy with or without intravenous oxytocin
Number of subjects: 143
Study 7041450 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 gel plus an indwelling catheter
Number of subjects: 143
Study 31030879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (15-minute duration)
Number of subjects: 107
Study 31030879 — intervention group
Group type: COMPARATOR
Intervention: Control (no-instruction, relaxing music)
Number of subjects: 107
Study 27633250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sembragiline (1 mg daily)
Number of subjects: 16
Study 27633250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sembragiline (lower doses)
Number of subjects: 16
Study 27633250 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy elderly subjects)
Number of subjects: 16
Study 26200038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 124
Study 26200038 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 124
Study 21517701 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) 18, 36 or 72 mg/day
Number of subjects: 401
Study 21517701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 21673083 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy (OMT) protocol consisting of myofascial release of the thoracic inlet, pectoral traction, rib raising, thoracic pump, and abdominal pump for 15 minutes.
Number of subjects: 21
Study 21673083 — intervention group
Group type: COMPARATOR
Intervention: Control group engaged in conversation with the researcher for 15 minutes.
Number of subjects: 21
Study 18583105 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO depression guideline with one day training
Number of subjects: 497
Study 18583105 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO depression guideline only (information group)
Number of subjects: 497
Study 18583105 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninformed)
Number of subjects: 497
Study 16528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-cholesterol
Number of subjects: 722
Study 16528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 722
Study 16528977 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 722
Study 16528977 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride
Number of subjects: 722
Study 16528977 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol
Number of subjects: 722
Study 12581034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care from a group of seven midwives in collaboration with medical staff
Number of subjects: 1000
Study 12581034 — intervention group
Group type: COMPARATOR
Intervention: Standard care from a variety of midwives and medical staff
Number of subjects: 1000
Study 15505943 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological stimulation via hemisphere-specific stimulation using visual or tactile stimulation or modified text
Number of subjects: 0
Study 15505943 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological intervention
Number of subjects: 0
Study 9432405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vindesine plus mitomycin C (PVM)
Number of subjects: 105
Study 9432405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vindesine plus ifosfamide (PVI)
Number of subjects: 105
Study 9432405 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus vindesine (PV)
Number of subjects: 105
Study 1576046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (200 micrograms)
Number of subjects: 0
Study 1576046 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 0
Study 1576046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1576046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine and Clonidine
Number of subjects: 0
Study 1576046 — intervention group
Group type: COMPARATOR
Intervention: Clonidine, Moxonidine, and Placebo
Number of subjects: 0
Study 1576046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0
Study 6419954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal reconstructive surgery
Number of subjects: 79
Study 6419954 — intervention group
Group type: COMPARATOR
Intervention: Control (observation without treatment)
Number of subjects: 79
Study 29059377 — intervention group
Group type: EXPERIMENTAL
Intervention: Power setting at 10 W
Number of subjects: 21
Study 29059377 — intervention group
Group type: COMPARATOR
Intervention: Power setting at 6 W
Number of subjects: 21
Study 27178974 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention on cardiovascular risk factors in high-risk hypertensive patients (ESCAPE trial)
Number of subjects: 256
Study 25038532 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step consent process (consented intervention arm participants for exams after randomization)
Number of subjects: 73036
Study 25038532 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from screening centers
Number of subjects: 73036
Study 25038532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall non-compliance rate
Number of subjects: 73036
Study 23363713 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily (Group 2)
Number of subjects: 120
Study 23363713 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding folic acid 5 mg/day, vitamin B(12) 500 µg twice daily and probucol 500 mg twice daily (Group 3)
Number of subjects: 120
Study 23363713 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive medication (Group 1)
Number of subjects: 120
Study 20868458 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (0.5‐2 mg/day)
Number of subjects: 66
Study 20868458 — intervention group
Group type: COMPARATOR
Intervention: divalproex (60‐120 μg/mL)
Number of subjects: 66
Study 19288773 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention including domiciliary telesurveillance and telepsychology at home
Number of subjects: 0
Study 16027128 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 76
Study 16027128 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 76
Study 16027128 — intervention group
Group type: COMPARATOR
Intervention: Training and supervision
Number of subjects: 76
Study 12771007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol (n=75)
Number of subjects: 150
Study 12771007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=75)
Number of subjects: 150
Study 11829701 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide (two 180‐microg/kg boluses, 10 minutes apart, with a continuous infusion of 2.0 microg/kg per minute; n = 1040)
Number of subjects: 2064